Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351459 | 0.74 | L3MBTL1 (0.37) | ADORA2B | |
| SCHEMBL2348788 | 0.72 | ADORA2B (0.38) | ADORA2B | |
| SCHEMBL15329750 | 0.71 | — | — | |
| SCHEMBL18516333 | 0.71 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL11163319 | 0.69 | MAPT (0.36) | ADORA2BMAPT | |
| SCHEMBL11164505 | 0.68 | MAPT (0.35) | ADORA2BMAPT | |
| SCHEMBL1224966 | 0.68 | TLR8 (0.41) | MAPT | |
| SCHEMBL591865 | 0.68 | DRD2 (0.44) | ADORA2BMAPT | |
| SCHEMBL2351474 | 0.67 | TLR8 (0.38) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24802481 | 0.67 | GRIN2B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-1601659-B1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ADRB3, DRD3, OPRL1 | ADORA2B 187/4885MAPT 1307/4885PDE4A 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.